Get started

NVO

$NVO Short Setup | EMA Wall Stops Bulls, Downside Active🎯 NVO Bearish Breakdown: 200 EMA Rejection Setup 🐻 📊 Asset Overview Novo Nordisk (NVO) - NYSE Type: Swing/Day Trade Opportunity Bias: Bearish Reversal Confirmed ⚠️ 🔍 Technical Analysis The bulls just got rejected harder than a bad pickup line at the 200 EMA! 📉 We're seeing strong bearish momentum building up with heavy downside pressure taking control. The market structure screams reversal, and bears are flexing their dominance. Key Technical Factors: 🚫 200 Exponential Moving Average acting as dynamic resistance 📉 Bearish momentum accelerating with high selling pressure 🔄 Clear market structure reversal pattern forming 🐻 Bears in full control of price action 💰 Trade Setup - "The Thief Strategy" 🎯 Entry Strategy Layering Method - Multiple limit orders for optimal positioning: Layer 1: $53.00 Layer 2: $52.00 Layer 3: $51.00 Feel free to add more layers based on your risk appetite and account size! 🛑 Stop Loss Thief SL: $56.00 ⚠️ Risk Disclaimer: This is MY stop loss level. You're the captain of your own ship - adjust based on your risk tolerance and trading plan. Trade at your own risk! 🎯 Target Zone Primary Target: $44.00 📍 Why $44? Strong support confluence + oversold conditions + potential bull trap zone. Smart money takes profits where the crowd panics! ⚠️ Profit Taking Note: This is MY target. You make your money, you take your money. Don't be greedy - secure those gains when YOUR plan says so! 🔗 Related Pairs to Watch Keep your eyes on these correlated assets for confirmation: 📈 Pharma/Healthcare Sector: NYSE:LLY (Eli Lilly) - Direct competitor in diabetes/obesity space NASDAQ:SNY (Sanofi) - European pharma correlation AMEX:XLV (Healthcare ETF) - Sector-wide momentum gauge 💵 Currency Impact: TVC:DXY (US Dollar Index) - Strong dollar = pressure on international stocks $EUR/USD - Danish Krone correlation (Denmark-based company) 💊 Related Healthcare Plays: NYSE:JNJ (Johnson & Johnson) - Large-cap healthcare sentiment NYSE:PFE (Pfizer) - Big pharma correlation Watch for divergences or confirmations across these pairs to validate the bearish thesis! 📝 Key Points Summary ✅ 200 EMA rejection = institutional selling zone ✅ Bearish market structure confirmed ✅ Multiple entry layers = better average price ✅ Strong support target at $44 = ideal exit zone ✅ Risk management is KING 👑 ⚡ The Thief's Edge This "layering strategy" lets you build positions gradually while managing risk like a pro. Instead of going all-in at one price, you spread your entries to capture the best average. It's not about timing the perfect entry - it's about stacking the odds in your favor! 🎲 🎭 The Thief Strategy: A playful nickname for layered limit order entries. Trade responsibly and within your means. ✨ If you find value in my analysis, a 👍 and 🚀 boost is much appreciated — it helps me share more setups with the community! #NVO #NovoNordisk #BearishSetup #SwingTrading #DayTrading #TechnicalAnalysis #StockMarket #NYSE #ThiefStrategy #LayeringStrategy #PharmaStocks #200EMA #BearishReversal #TradingIdeas #PriceAction #RiskManagement #Healthcare #BiopharmaTrade
NYSE:NVOShort
by The-Thief
7
Time to go Long NVO?NVO has had a tough year. It's down 53% ytd. I accumulated 100 shares at $50 in August and stupidly held the bag despite the price hitting my target of 60. The price is back down around $50, and looking like a good time to buy. If you look down at the RSI the last 2 times it sunk to oversold, it triggered runs of 10-20pts. Personally, I think the stories of increased competition are overblown. This is the largest company in Europe and still a leader. The share price needs help from some US gov't policy, but it's definitely in its accumulation zone again. Moreover, it looks like it could finally break the downward trendline started back in December. Share prices dopped to $50 once again today on the news that it's bidding on Metsera. And on the news, I bought another 100 shares. This trade is active.
NYSE:NVOLong
by brendanvanson
$NVO end of bearish trend. - NYSE:NVO has exited the bearish trend and very soon it will be doing a trend reversal and enter a new trend. - if it consolidates, trade sideways or up is yet to be seen. - However, if a stock exits such a prominent downtrend then move to the upside after breakout is explosive. - Fundamentals are backing $NVO. - R&D is crown jewel of this company - Operation efficiency is improving under the new leadership - Entering new markets like India would unlock huge market for NYSE:NVO - Pills are the next growth lever for the company. - On top of that, Valuation is too cheap for an exploding TAM of weight loss and it's health benefit.
NYSE:NVOLong
by bigbull037
$NVO supertrend 3-5x in next 5 years- Don't trade NYSE:NVO but invest. - NYSE:NVO is in 28 years of uptrend and the innovation DNA of this company will prove the investors yet again. - Reasons to be bullish on NYSE:NVO - NYSE:NVO is making pills for weightloss but that not only helps in weight management but also reduces risk of heart attack, stroke, control diabetes. - Injections are costly to manufacture and has less shelf life on top of that in order to take injections one often require assistance whereas pills is very easy to consume just like vitamins. - NYSE:NVO move towards oral pills unlock massive TAM ( technical addressable market ) as millions of people are suffering with obesity, diabetes, chronic heart and brain disease that having access to this pill would be like getting a vitamin pill. - NYSE:NVO is like index fund for denmark just like NASDAQ:QQQ where majority of weight is taken by big tech stocks. Danish funds and people will continue to buy the dip regardless of whether NYSE:NVO is in bearish cycle or bullish. - NYSE:NVO valuation is super cheap and is even lower than NYSE:NVO started the injectibles for weight loss. - NYSE:NVO leadership is reflective and has conducted reduction in workforce which is rare for healthcare company as healthcare company usually run like welfare/government bloated. CEO is ready to keep startup like culture and promote innovation DNA alive. - I believe NYSE:NVO offers asymmetric opportunity and is going to be a long term compounder for years to come.
NYSE:NVOLong
by bigbull037
1
Why Did Novo Stock Fall So Sharply YesterdayNovo Nordisk shares plunged nearly 20–23% on July 29, 2025, marking its worst trading day since Black Monday in 1987. Significant Downgrade of 2025 Financial Outlook The company revised its sales growth forecast for 2025 down to 8–14%, from its prior guidance of 13–21%, and reduced expected operating profit growth from 16–24% to 10–16%. This adjustment was attributed to weaker-than-expected demand for Wegovy and Ozempic, and rising competitive pressures #TheWallStreetJournal I will start my accumulation using DCA, but will be happier to start buying this stock heavily from $47 zone. trade with care. I look forward to connecting with you
NYSE:NVOLong
by ForexClinik
1
Novo Nordisk (Revised) | NVO | Long at $47.78**This is a revised analysis from February 5, 2025: I am still in that position, but added significantly more below $50** Novo Nordisk NYSE:NVO is now trading at valuations before its release of Wegovy and Ozempic... From a technical analysis perspective, it's within my "major crash" simple moving average zone (gray lines). When a company's stock price enters this region (especially large and healthy companies) I always grab shares - either for a temporary future bounce or a long-term hold. While currently trading near $47 a share, I think worst case scenario here in 2025 is near $38-$39. Tariffs may cause a recession in the second half of 2025, so no company would be immune. As mentioned above, I am still a holder at $86.74. However, I went in much heavier within my "major crash" simple moving average band and have a final entry planned near $38-$38 (if it drops there). My current cost average is near $55.00. Why do I still have faith in NYSE:NVO ? Because no one else does right now, yet it generated $42 billion in revenue, $14 billion in profits, and has significant cash flow YoY. The company has a massive pipeline, despite Wegovy and Ozempic competition, and I think the market is undervaluing its position in the pharmaceutical industry. Revised Targets in 2028: $60.00 (+25.6%) $70.00 (+46.5%) $80.00 (+67.4%)
NYSE:NVOLong
by WorthlessViews
$NVO Accumulating long term compounder! - Previously, I have shorted NYSE:NVO when it was in $75-85 when moat was weakening and then went long around $58 to $75 for 40% on the long side. Everything is documented in my two posts. - People are asking me if NYSE:NVO is cheap or not. After cutting guidance, I believe most of the estimates for EPS about NYSE:NVO are way off which would be revised downwards. - At the same time, I believe NYSE:NVO has kitchen sinked their guidance because of new CEO transition which is very common in the publicly traded company. - NYSE:NVO might not be cheap after cutting guidance honestly but not overvalued either. - NYSE:NVO could be a dead money for some time 6 months, 1 year or 2 years who knows? - But I know that weight loss industry in general is growing overall at least till 2030 and beyond. - Some concerns I have is NYSE:NVO leadership is getting challenged by NYSE:LLY so it could be possible that NYSE:NVO might get lesser piece of the pie. However, overall piece is growing along with it so NYSE:NVO should continue to grow but at a lower rate than earlier. - Net free cash flow should grow and company might return on investment to shareholders via share buybacks? - Finally, I am buying NYSE:NVO in increments and have bought first lot of shares in $50.xx and will continue to add more if it drops more. I think NYSE:NVO can test 200 monthly moving average @ $35. - I have marked the accumulation box in the chart for your reference.
NYSE:NVOLong
by bigbull037
1
Is Novo Nordisk a buy? Novo Nordisk $NYSE: NVO plummets 22% on July 29, wiping out $57.5B in market value! Here's what's happening and how I see it. Here’s the breakdown on why the stock hit its lowest since Nov 2022: Slashed 2025 Guidance: Sales growth cut to 8–14% from 13–21%, operating profit to 10–16% from 16–24%. Weak U.S. demand for Wegovy & Ozempic, plus competition from cheaper compounded GLP-1 drugs (i.e. grey market), cited as key issues. CEO Shake-Up: Lars Fruergaard Jørgensen out, Maziar Doustdar in as CEO effective Aug 7. Investors worry Doustdar’s limited U.S. experience could hurt Novo’s edge in its biggest market (57% of sales). Competition: Eli Lilly’s Zepbound (20.2% weight loss vs. Wegovy’s 13.7%) & Mounjaro are stealing market share. Compounded GLP-1s from Hims & Hers add pricing pressure. Here's what I see: There's a strong bearish sentiment, but the stock is very underpriced. Considering the current stock price, EPS is at an all-time high. This means investors get more earnings for their stock. P/B, P/E, and P/S ratios are at the lowest level since 2017! This is despite revenue growth of 25%+ for 3 consecutive years. Operating margins are still quite healthy. The company still has a very significant share (over 50%) of the GLP1 drugs worldwide. The valuation of this company is now at the best level of the last 7-8 years. There might be more volatility ahead, but I see the recent price drop as an opportunity to buy a pharma giant at a big discount, giving investors a margin of safety. Quick note: I'm just sharing my journey - not financial advice! 😊
NYSE:NVOLong
by HenriqueCentieiro
2
$NVO offers solid risk to reward for long term buyers! - I had previously called out that NYSE:NVO would have more pain to come when it was in $85-90s I have attached the link with this post for my reader's reference. - Now, I am turning bullish on this name given these prices and compressed multiples for the growth prospects it offers. Fundamentally, Year | 2025 | 2026 | 2027 | 2028 EPS | 3.93 | 4.78 | 5.41 | 5.97 EPS growth% | 25.41% | 21.60% | 13.19% | 10.24% For a quality name growing EPS > 20% deserves a fair forward multiple of 25. | Year | Bear (fp/e = 15) | Cons. Base (f. p/e = 20) | Base (fpe = 25) | Bull Case (fpe=30) | 2025 | $58.95 | $78 |. $98.25. |. $117.9 | 2026 | $71.7 | $95 |. $119. |. $143.4 | 2027 | $81.15 | $108 |. $135 | $162.3 | 2028 | $90 | $119 |. $149.25 | $179.1 As you can see, If you buy NYSE:NVO under $60 then you will be making money even if multiple remains compressed i.e bear case. Only thing you have to do is hold and returns would amplify once there is optimism back in the market which will lead to multiple expansion. My fair value for NYSE:NVO for this year is $78 based on the conservative base case.
NYSE:NVOLong
by bigbull037
HIMS puked up its Wegovy today!Hims & Hers Health HIMS shares were down more than 34.63% in Monday trading, while Novo Nordisk NVO stock was down over 5% after Novo Nordisk said it has halted its collaboration with Hims & Hers on the sale of weight loss drugs, including Wegovy. The two companies launched a collaboration in April to bundle Wegovy through Hims & Hers' telehealth platform. Novo Nordisk said direct access to the drug would no longer be available through Hims & Hers Health because the company "has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk." This stock failed to catch a bid despite the equity markets strong.
NYSE:HIMS
by Trading-Capital
3
Novo Nordisk (NVO) – Oversold Reversal + Earnings CatalystNovo Nordisk (NVO) has declined 61.13% from its all-time high of $148 (June 2024), finding support at $57.55. Over the past two weeks, the stock has rebounded over 15%, currently trading around $66.30, with strong reversal signals just ahead of earnings. This setup presents a compelling opportunity, both technically and fundamentally, for a tactical trade or a longer-term position. Simply Wall St 🔍 Technical Highlights: ✅ Rebound from long-term ascending trendline (~$57–58 zone) ✅ RSI rising from oversold levels (28 → 32 and climbing) ✅ MACD approaching a bullish crossover, indicating momentum shift ✅ Two consecutive green weekly Heikin Ashi candles post-bottom ✅ Defined risk with invalidation below $57 support 📈 Trade Setup: 🟢 Entry Zone: $66–68 (current price range) 🔴 Stop Loss: Below $57.00 (break of structure and breakout base) MarketWatch +6 StockAnalysis +6 Simply Wall St +6 ✅ TP1: $78 – previous support zone ✅ TP2: $90 – February 2025 high before the selloff ✅ TP3: $110 – around December 2024’s local top 🗓️ Earnings – May 7, 2025 🔹 Analysts project ~19.7% YoY revenue growth 🔹 Continued strong demand for Ozempic and Wegovy 🔹 Forward P/E ratio at 16.33, below industry average 🔹 Robust margins and high institutional ownership 🔹 Significant free cash flow and a promising innovation pipeline StockAnalysis 📌 This appears to be a high-quality oversold bounce with a well-defined risk/reward structure ahead of a significant earnings catalyst. Whether you're considering a swing trade or building a core position, this setup aligns both technical and fundamental factors. Let’s monitor how this unfolds. 📊🔬 Disclaimer: This is not financial advice – just sharing my perspective. Please conduct your own research before making investment decisions.
NYSE:NVOLong
by FinanceProSignals
2
Novo Nordisk: 50% Drops Lead to Amazing GrowthFundamentals : Take a look at NVO in 1999-2000, 2003, 2008, 2016 and June 20024-2025. Every time it dropped about 50%, that lead to a huge rally for years! NVO has secured contracts with Medicaid for their diabetes and other drugs. It is not going anywhere. It has fallen 50%. We either hold or buy more. Technicals : uHd + extreme indicator +u3 volume last month +horizontal support + a-b-c + key fib pb Projection: 200 to 250 within two years, tentatively.
NYSE:NVOLong
by Rocketman
Opening (IRA): NVO March 28th 76 Covered Call... for a 74.50 debit. Comments: Taking what amounts to a modest directional shot with a break even below the 52-week lows, selling the -75 delta call against shares to emulate the delta metrics of a 25 delta short put, but with the built-in defense of the short call. Metrics: Buying Power Effect/Break Even: 74.50 Max Profit: 1.50 ROC at Max: 2.01% 50% Max: .75 ROC at 50% Max: 1.00 Will generally look to take profit at 50% max and/or roll out the short call if my take profit isn't hit by expiry.
NYSE:NVOLong
by NaughtyPines
Buy Opportunity for NVONovo Nordisk A/S – Financial Summary and Outlook (2024): Sales Growth: Up 23% in Danish kroner (DKK 204.7 billion) and 24% at constant exchange rates (CER). Operating Profit: Increased by 21% (DKK 91.6 billion). Net Profit: Rose 18% to DKK 72.8 billion. Product Highlights: Wegovy (Obesity): Sales surged 48% in Q3 (DKK 17.3 billion). Ozempic (Diabetes): Slight sales dip but remains a key contributor. Challenges: CagriSema Trial: Missed expected weight-loss targets, leading to stock decline. Outlook: Adjusted sales growth forecast: 23%-27%; operating profit: 21%-27% (CER). Focus remains on high-demand products (Wegovy, Ozempic) and R&D for future growth.
NYSE:NVOLong
by datavanza
$NVO more pain ahead! Headed down to $46-55 - NYSE:NVO was one of the hottest stocks of 2024 is now facing immense challenges by other healthcare companies in weight loss drug. - With weak results, it sets up for disappointment for 1-2 quarters. Quick turnaround in experiments isn't feasible and would need considerable time to show promising results. - It's better to put it on watchlist, attend earning call however it is likely that it might underperform FY 2025 or alteast first half of FY 2025.
NYSE:NVOShort
by bigbull037
9
Novo Nordisk | NVO | Long at $86.74The Good: NYSE:NVO expects its GLP-1 drugs Wegovy and Ozempic to soon come off the Food and Drug Administration's official shortage list. Just reported better-than-expected net profit in Q4 2024, amid soaring demand for its obesity drugs. Revenues for the Q4 2024 came in at $11.6 billion, up 30% compared to the same quarter in 2023. From a technical analysis perspective, hovering near my historical simple moving average which may lead to a near-term price increase due to positive earnings The Bad: Slower growth in 2025 (16%-24% for 2025 vs 18%-26% in 2024). Chart has been on a major run since 2020 and may be due for further correction. Personally, the positives outweigh the negatives given the obesity drug demand. Thus, at $86.74, NYSE:NVO is in a personal buy zone. Targets: $96.00 $105.00
NYSE:NVOLong
by WorthlessViews
1
Novo Nordisk (NVO): Beautiful Reversal Pattern is emerging Novo Nordisk price has charted a famous and beautiful reversal pattern - Head & Shoulders. We have 3 peaks with the middle one the tallest also called Head. The Right Shoulder inclines down so the magnitude of the bearish move is strong. The dotted line between valleys of the Head is called a Neckline. The bearish target for this reversal is located at the distance of Head's height subtracted from the breakdown point on the Neckline. So, the target is at $89. This area aligns very well with the bottom of last October and the peak of last May.
NYSE:NVO
by aibek
8
Can Market Turbulence Create Future Innovation?In a dramatic turn of events that sent shockwaves through the pharmaceutical industry, Novo Nordisk's recent setback with its experimental obesity drug CagriSema presents a fascinating case study in market resilience and scientific progress. The company's stock plummeted 24% after trial results showed a 22.7% weight reduction efficacy, falling short of the anticipated 25% target. Yet, beneath this apparent disappointment lies a deeper story of pharmaceutical innovation and market adaptation. The obesity treatment landscape stands at a pivotal crossroads, with the market experiencing exponential growth from its modest beginnings to a staggering $24 billion industry in 2023. Novo Nordisk's journey, alongside competitor Eli Lilly, exemplifies how setbacks often catalyze breakthrough innovations. The CagriSema trial, involving 3,400 participants, represents a clinical study and a testament to the industry's commitment to addressing global health challenges. Looking ahead, this moment of market recalibration might well be remembered as a turning point in the evolution of obesity treatment. With projections suggesting a potential $200 billion market by the early 2030s, the current turbulence could drive even greater innovation and competition. The fact that only 57% of trial participants reached the highest CagriSema dose points to untapped potential and future opportunities for optimization, suggesting that today's apparent setback might pave the way for tomorrow's breakthroughs.
NYSE:NVOShort
by UDIS_View